Pre-exposure prophylaxis involves people who do not have HIV taking antiretroviral drugs when they are at risk of exposure to HIV in order to prevent infection. The drugs are usually taken as pills (oral PrEP). Visit our Microbicides section for information on the development of topical PrEP products.

PrEP: latest news

PrEP resources

  • How to get PrEP in the UK

    In England, PrEP is available to people taking part in the PrEP Impact trial.In Wales, Scotland and Northern Ireland, PrEP is available through NHS sexual health clinics.It...

    From: Factsheets

    Information level Level 2
  • Pre-exposure prophylaxis (PrEP)

    PrEP is highly effective in preventing the sexual transmission of HIV. For PrEP to work well, it’s important to take the pills regularly.While PrEP can...

    From: Factsheets

    Information level Level 2
  • Using anti-HIV drugs to prevent HIV

    The goal of HIV treatment is an undetectable viral load. An undetectable viral load means that your blood has a level of HIV below the level which...

    From: Booklets

    Information level Level 2
  • PrEP

    This briefing paper provides an overview of pre-exposure prophylaxis (PrEP) for people planning, commissioning or providing HIV prevention activities in the UK. It does this by reviewing...

    From: HIV prevention briefing papers

  • Pre-exposure prophylaxis

    Pre-exposure prophylaxis is an experimental HIV-prevention strategy that would use antiretrovirals (ARVs) to protect HIV-negative people from HIV infection....

    From: Preventing HIV

    Information level Level 4

PrEP features

PrEP news from aidsmap

More news

PrEP news selected from other sources

  • PrEP Use Among Gay and Bi Men Hits a New High

    A third of at-risk gay and bi men are now using Truvada for HIV prevention, the CDC says.

    22 hours ago | Poz
  • On-Demand PrEP With TDF/FTC Not Associated With Clinically Relevant Decline in Kidney Function

    On-demand pre-exposure prophylaxis (PrEP) with tenofovir disoproxil fumarate (TDF)/emtricitabine (FTC) is not associated with a significant relevant in kidney function, especially among young people with low pill use and high baseline estimated glomerular filtration rate, investigators in France found.

    20 March 2019 | Contagion Live
  • Jean-Michel Molina, MD, on Biomedical Failures of PrEP: Rare, But Serious

    "There are multiple reasons for PrEP failures and they could be at any point in the PrEP continuum of care. From people who may not use their pills as recommended, to a health care system that is not able to provide access to PrEP for people in need, it could be also the physicians who are not ready to prescribe PrEP or not aware that they could use PrEP for preventing HIV in high-risk patients. It could be also the test that we use sometimes that are not able to detect acute HIV infection. And, if you start PrEP in someone with acute HIV infection you will see more resistance."

    14 March 2019 | Contagion Live
  • Gilead's Descovy snared its PrEP data, but can it stand up to Truvada generics?

    Gilead Sciences has the data it’ll need to start transitioning patients taking Truvada for PrEP over to Descovy, a drug with a longer patient life. But once Truvada generics hit, it might be a different story.

    14 March 2019 | FiercePharma
  • Sadiq Khan: Cash row is denying Londoners access to HIV ‘wonder drug’

    The London mayor said: “I’m shocked that the Government is failing to provide local authorities in London with the funding they need to provide PrEP to all those who could benefit.”

    12 March 2019 | Evening Standard
  • How Many More Must Needlessly Contract HIV Before We Ensure Proper Access To PrEP?

    Local authorities are legally responsible for providing information and services that can help prevent HIV. We are calling on local authorities in London to urgently double the number of places offered to them as part of the trial. Other parts of England have shown decisive leadership on PrEP access, it’s time for London to do the same.

    12 March 2019 | Huffington Post
  • Here's how to get onto England's PrEP trial

    Will Nutland of Prepster explains.

    06 March 2019 | Gay Star News
  • Should the NIH Break HIV Prevention Drug Truvada's Patent?

    Should a biotech giant holding a valuable patent be forced to give it up if doing so would serve the public good? That’s the mounting debate over Gilead Sciences’ hold on an HIV prevention treatment, which some say is too expensive and should be available to all.

    05 March 2019 | Fortune
  • Ireland: The new HIV crisis needs a better response

    HIV is a public heath issue, but a spike in diagnoses in Ireland seems to be going unchecked. New figures published last week show there were 531 new cases of HIV infections diagnosed in 2018, an increase from 492 in 2017. There is now a new diagnosis of HIV in Ireland every 17 hours; Ireland’s rate of new diagnoses stood at 10.2 per 100,000 people in 2017, while the European average is 6.2 per 100,000.

    04 March 2019 | Irish Times
  • Examining the Truvada #BreakThePatent Debate: Gilead Responds

    A review of how patents affect access to Truvada, and Gilead's response on calls for march-in rights to be granted on patents in order to facilitate access.

    04 March 2019 | IPWatchdog.com
More news
Tell us why you visited aidsmap today
minimise

Could you help us by answering three questions on why you’ve visited aidsmap today?

You can close this questionnaire and come back to it later. Just click on the pink circle.

What prompted you to visit aidsmap today?

What exactly are you looking for? What specific questions do you need answered?

Have you found what you were looking for?

close

Thank you for your feedback

Thank you very much for taking time to fill in this questionnaire. NAM really values your feedback. It helps make the information we provide better.

If you have any other comments on the content of this website, we would be interested to hear from you. Please email info@nam.org.uk.

Our information levels explained

  • Short and simple introductions to key HIV topics, sometimes illustrated with pictures.
  • Expands on the previous level, but also written in easy-to-understand plain language.
  • More detailed information, likely to include medical and scientific language.
  • Detailed, comprehensive information, using medical and specialised language.
Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap
close

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.